口服胰岛素预防1型糖尿病的遗传应答预测因素
基于TrialNet口服胰岛素预防试验TN07中552名1期1型糖尿病亲属的DNA,使用TEDDY-T1DExomeChip基因分型,采用Cox模型分析HLA单倍型、33个预设T1D相关SNP、T1D遗传风险评分2(GRS2)及T2D多基因评分与口服胰岛素应答的关联。GLIS3 rs7020673在次要分层1(SS1)中与应答显著相关(BH校正P=0.031,协变量调整后P=0.022),提示遗传差异可区分应答者与非应答者。
要点
- GLIS3 rs7020673与SS1层口服胰岛素应答显著相关(BH校正P=0.031)。
- HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02在SS1层与更好应答名义相关。
- 整体队列中T1D-GRS2>12.5者口服胰岛素应答优于≤12.5者(未调整P=0.003)。
核心结论
- 遗传差异可区分口服胰岛素预防1型糖尿病的应答者与非应答者。
- 遗传学有望通过识别可能受益于T1D修饰治疗的个体实现精准医学。
研究设计与样本
- TrialNet口服胰岛素预防试验TN07纳入560名1期T1D患者亲属,其中552名有DNA者用TEDDY-T1DExomeChip基因分型。
- 采用Cox模型分析HLA单倍型、33个预设T1D相关SNP、T1D-GRS2及T2D多基因评分与口服胰岛素应答的关联。
- 主要分析P值经Benjamini-Hochberg(BH)多重比较校正,未通过校正者视为名义显著。
主要发现
- GLIS3 rs7020673在SS1层与口服胰岛素应答显著相关(BH校正P=0.031,协变量调整后P=0.022)。
- SS1层中HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02与更好应答名义相关(HR 0.22 vs. 1.09;未调整P=0.031;调整P=0.045)。
- TNFAIP3和CTLA4在至少一个分层中与更差应答名义相关。
- 探索性分析中,整体队列T1D-GRS2>12.5者应答较好(HR 0.68),≤12.5者应答较差(HR 2.10;未调整P=0.003;调整P=0.006)。
- SS1层中较低的前胰岛素划分T2D多基因评分与更大治疗获益相关,另一次要分层中较低的肥胖划分T2D多基因评分与更大治疗获益相关。
关键数值与推荐
- SS1层定义为低第一时相胰岛素释放,共55例,对口服胰岛素应答显著更好。
- GLIS3 rs7020673与SS1层口服胰岛素应答显著相关,BH校正P=0.031(未调整协变量),调整后P=0.022。
- SS1层HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02与更好应答名义相关,HR 0.22 vs. 1.09,未调整P=0.031,调整P=0.045。
- 整体队列T1D-GRS2>12.5者口服胰岛素应答HR 0.68,≤12.5者HR 2.10,未调整P=0.003,调整P=0.006。
临床怎么用
- 对1期T1D亲属可考虑检测GLIS3 rs7020673、HLA单倍型及T1D-GRS2以辅助识别口服胰岛素潜在获益者。
- SS1层(低第一时相胰岛素释放)患者可能从口服胰岛素预防中获益更多,遗传标志物可进一步分层。
- 遗传分层有望指导T1D修饰治疗的精准选择,但需外部验证后用于临床决策。
局限性
- SS1层样本量较小(n=55),部分关联仅为名义显著,需更大样本验证。
- 研究为探索性遗传关联分析,未建立因果机制。
- T2D多基因评分相关结果来自探索性分析,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The TrialNet Oral Insulin Prevention Trial TN07 tested oral insulin to prevent stage 3 type 1 diabetes (T1D) in 560 relatives with stage 1 T1D of individuals with T1D. Of the three predefined risk strata, participants in secondary stratum 1 (SS1) (n = 55), characterized by low first-phase insulin release, responded significantly better to oral insulin. We aimed to identify genetic factors associated with treatment response. RESEARCH DESIGN AND METHODS: The TEDDY-T1DExomeChip was used to genotype 552 participants with available DNA. Cox models examined associations between response to oral insulin and HLA haplotypes, 33 preselected T1D-associated single nucleotide polymorphisms, T1D genetic risk score 2 (GRS2), and type 2 diabetes (T2D)-associated polygenic scores. For primary analyses, P values were Benjamini-Hochberg (BH) corrected for multiple comparisons; results not passing correction were considered nominal. RESULTS: GLIS3 rs7020673 was significantly associated with response to oral insulin in SS1 (BH-corrected P = 0.031 without and P = 0.022 with covariate adjustment). Additional nominal associations included better response with HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02 (hazard ratio [HR] 0.22 vs. 1.09; unadjusted P = 0.031; adjusted P = 0.045) in SS1 and worse responses with TNFAIP3 and CTLA4 in at least one stratum. In exploratory analyses, participants with T1D-GRS2 >12.5 responded better to oral insulin (HR 0.68) than those with T1D-GRS2 ≤12.5 (HR 2.10; unadjusted P = 0.003; adjusted P = 0.006) in the overall cohort, and lower proinsulin- and obesity-partitioned T2D polygenic scores were associated with greater treatment benefit in SS1 and in another secondary stratum, respectively. CONCLUSIONS: Genetic differences distinguish responders from nonresponders to oral insulin for T1D prevention. Genetics may enable precision medicine by identifying individuals likely to benefit from T1D-modifying therapies.
引用
- You L, Parikh HM, Triolo TM, et al. Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026. PMID: 41364459. doi:10.2337/dc25-2006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。